Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of KVD900 Followed by Crossover Sub-studies of KVD900 Formulations, and Food Effect in Healthy Male Volunteers

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of KVD900 Followed by Crossover Sub-studies of KVD900 Formulations, and Food Effect in Healthy Male Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sebetralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions; First in man
  • Sponsors KalVista Pharmaceuticals

    • Most Recent Events

    • 16 Feb 2023 According to a KalVista Pharmaceuticals media release, data from this study will be presented at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27. All results will be shared as a poster presentation and Q&A on Sunday, February 26 from 9:45-10:45 a.m. CST in the Convention Center, Lobby Level, Hall 2.
    • 05 Jul 2022 According to a KalVista Pharmaceuticals media release, data from the study was presented at the EAACI 2022 conference.
    • 22 Mar 2022 According to a KalVista Pharmaceuticals media release, data from the study was published in Clinical & Experimental Allergy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top